CClinicalTrials.gg
CompletedNCT05373394POG-CUpdated Sep 7, 2022

Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area

An observational study in Cognitive Disorders, Motor Disorders and Low-grade Glioma, sponsored by University Hospital, Tours. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-07.

Sponsored by University Hospital, Tours · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

Background : The supplementary motor area is the most common/preferential brain location of LGG. This area plays an important role in many motor and cognitive functions such as motor initiation, bimanual coordination and executive functions. Many studies describe the supplementary motor area syndrome resulting from lesions in this area. News managements for LGGs consisting in intraoperative mapping in awake patients reduce significantly neurological disorders and increase also the overall survival . However, the literature does not provide data concerning motor and cognitive functions in a long term and their consequences in the quality of life of patients.

Objective : The aim of our research project is to identify whether there are some motor or neurocognitive deficit in the short and the long term in a population of patients who have medical story of LGG resection in the supplementary motor area.

Read the detailed description

Patients and Methods : 20 patients who have medical story of LGG in the supplementary motor area and 20 patients who have medical story of LGG resection in other locations are recruited. Firstly, patients have to complete a self-assessment questionnaire about their quality of life, sent by regular mail or e-mail. Then, patients are admitted on the same day as their follow up visit and underwent motor and neurocognitive screening tests ( "Bilan des 400 points", Tests of Attentional Performances) for an hour. The investigators will analyse data and compare between the 2 groups.

02

Conditions studied

  • Cognitive Disorders
  • Motor Disorders
  • Low-grade Glioma

Keywords

  • glioma
  • supplementary motor area
  • neurological disorders
03

In context

Glioma

1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.

This study's enrollment of 22 is below the median of 88 across 238 observational studies indexed under Glioma.

Browse Glioma studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 304 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with low-grade diffuse glioma resection visiting the university hospital for a follow-up neurosurgical consultation

Inclusion criteria

  • 18 years of age or older
  • Have a history of low-grade diffuse glioma resection
  • Visiting the University Hospital for a follow-up neurosurgical consultation
  • Underwent awake surgery

Exclusion criteria

Exclusion Criteria:

  • Presence of cognitive disorders that do not allow the proposed test battery to be performed
  • Under guardianship or curatorship
  • Opposition to the participation to the research
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No

Groups and cohorts

  • Case

    patients with a history of surgical removal of diffuse low grade glioma located in the supplementary motor area

    Other: Test battery

  • Control

    patients with a history of surgical removal of diffuse low-grade glioma located in another brain area

    Other: Test battery

Interventions

  • OtherTest battery

    motor and neuropsychological test battery

06

What researchers measure

Primary outcomes

  1. motor tests in the case group - 400 point assessment

    analysis of the scores obtained at the tests 4 tests : * Hand mobility * Grip strength * Single-handed grasp and movement of objects * Two-handed grasp and movement of objects Minimum value = 0 Maximum value = 100 100/100 means that the various tests regain good motor skills and hand grasp

    Time frame: inclusion visit

  2. neuropsychological tests in the case group

    analysis of the scores obtained Phase alert system * Reaction time (RT) and standard deviation (SD) measurement with horn * Measurement of reaction times (RT) and standard deviation(SD) without horn * Measurement of the phase alert index Flexibility * Measurement of reaction times (RT) and standard deviation (SD) with hand change * Measurement of reaction times (RT) and standard deviation (SD) without hand change * Overall performance index * Speed accuracy trade off index * Number of wrong answers Incompatibility * Measurement of reaction times (RT) and standard deviation (SD) in compatible condition * Measurement of reaction times (RT) and standard deviation (SD) in incompatible condition * F (visual field) * F (hand) * F (incompatibility: fields \* hand) * Number of false responses RT min : 0 SD min : 0 No maximum value: calculation against standard values

    Time frame: inclusion visit

Secondary outcomes

  1. motor tests in the control group - 400 point assessment

    analysis of the scores obtained at the tests 4 tests : * Hand mobility * Grip strength * Single-handed grasp and movement of objects * Two-handed grasp and movement of objects Minimum value = 0 Maximum value = 100 100/100 means that the various tests regain good motor skills and hand grasp

    Time frame: inclusion visit

  2. neuropsychological tests in the control group

    analysis of the scores obtained Phase alert system * Reaction time (RT) and standard deviation (SD) measurement with horn * Measurement of reaction times (RT) and standard deviation(SD) without horn * Measurement of the phase alert index Flexibility * Measurement of reaction times (RT) and standard deviation (SD) with hand change * Measurement of reaction times (RT) and standard deviation (SD) without hand change * Overall performance index * Speed accuracy trade off index * Number of wrong answers Incompatibility * Measurement of reaction times (RT) and standard deviation (SD) in compatible condition * Measurement of reaction times (RT) and standard deviation (SD) in incompatible condition * F (visual field) * F (hand) * F (incompatibility: fields \* hand) * Number of false responses RT min : 0 SD min : 0 No maximum value: calculation against standard values

    Time frame: inclusion visit

  3. Brain MRI

    Analysis of the location of diffuse low-grade gliomas

    Time frame: inclusion visit

  4. Brain MRI

    Analysis of the lesion volume of diffuse low-grade gliomas

    Time frame: inclusion visit

  5. quality of life self-questionnaire carried out at home : sickness Impact Profile

    analysis of the results obtained 136 questions with responses True or False Minimum value = 0 Maximum value = 136 136/136 means that the quality of life is very negatively affected

    Time frame: inclusion visit

  6. fatigue self-questionnaire carried out at home : fatigue Impact Scale (FIS)

    analysis of the results obtained 40 questions with responses * It is quite true * It is rather true * It is neither true nor false * It is rather false * It is completely false

    Time frame: inclusion visit

07

Study locations

1 site
  • University hospital
    Tours, 37044, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05373394
Lead sponsor
University Hospital, Tours
Responsible party
Sponsor
First posted
May 13, 2022
Start date
May 19, 2022
Primary completion
Jun 23, 2022
Completion
Jun 23, 2022
Last update
Sep 7, 2022

Study contacts

Ilyess ZEMMOURA
principal investigator · University Hospital, Tours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion